Skip to main content
OpenTrials
Completed

NCT Number: NCT02143791

Evaluate St Jude Medical Prodigy Neuromodulation for FBSS or Chronic Pain of the Trunk and/or Limbs

The purpose of this study is to confirm long term efficacy and safety of the ProdigyTM neuromodulation system in the management of failed back surgery syndrome or chronic intractable pain of the trunk and/or limbs.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Metro Spinal Clinic, Caulfield, Australia

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient with chronic, intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with the following: failed back surgery syndrome or intractable low back and/or leg pain
  • Patient diagnosed with radiculopathy
  • Patient diagnosed with neuropathic pain
  • Patient is considered by the investigator as a candidate for implantation of a SCS system
  • Patient is ≥ 18 years of age
  • Patient must be willing and able to comply with study requirements
  • Patient must indicate his/her understanding of the study and willingness to participate by signing an appropriate Informed Consent Form

Exclusion criteria

  • Patient is diagnosed with ischemic pain
  • Patient is diagnosed with arachnoiditis
  • Patient is diagnosed with complex regional pain syndrome (CRPS I and II)
  • Patient is diagnosed with peripheral vascular disease (PVD)
  • Patient is diagnosed with diabetic neuropathic pain
  • Patient is diagnosed with chronic migraine
  • Patient is immune-compromised
  • Patient has history of cancer requiring active treatment in the last 6 months
  • Patient has a documented history of substance abuse (narcotics, alcohol, etc.) or substance dependency in the last 6 months
  • Patients with a SCS system or implantable infusion pump implanted previously
  • Patient has a life expectancy of less than one year
  • Patient is pregnant or is planning to become pregnant during the duration of the investigation
  • Patient is unable to comply with the follow up schedule
  • Patient needing legally authorized representative
  • Patient unable to read and write
  • Patient is currently participating in another clinical investigation with an active treatment arm.

Treatment and study plan

Burst and Tonic stimulation

Procedure

Primary outcomes

  1. Percentage Change From Baseline in Overall VAS at 3 Months

    Time frame: 3 months

    Percentage change in pain relief at the 3- month follow-up visit compared to baseline visit, as measured by the Visual Analog Scale (VAS). The VAS scale with a 10 cm (or 100 mm) line to indicate pain intensity progression with no pain (0) on the left end and worst pain (100) on the right end. Percent change is calculated as "[(post baseline baseline)/baseline] *100%" with positive numbers to represent increases and negative numbers to represent decreases.

Secondary outcomes

  1. Pain Relief

    Time frame: 3 Months

    Patient reported pain relief. Patients were asked to evaluate their pain relief over the past week in percentage with 0% being no pain relief and 100% being complete pain relief.

  2. Pain Relief

    Time frame: 6 Months

    Patient reported pain relief. Patients were asked to evaluate their pain relief over the past week in percentage with 0% being no pain relief and 100% being complete pain relief.

  3. Pain Relief

    Time frame: 12 Months

    Patient reported pain relief. Patients were asked to evaluate their pain relief over the past week in percentage with 0% being no pain and 100% being complete pain relief.

  4. Change in Pain Catastrophizing Scale

    Time frame: 12 Months

    The pain catastrophizing scale (PCS) is a validated scale containing 13 items to assess thoughts and feelings about pain while a person is experiencing pain. The total of all 13 items results in a minimum of 0 and a maximum of 54; scores above 30 indicate clinically significant pain catastrophizing. The mean change was calculated based on the value at 12 months minus the value at baseline.

  5. Number of Participants With Analgesic Reduction

    Time frame: 12 Months

    Patient reported analgesic usage during the 4 weeks preceding the 12-month follow-up visit, compared to the baseline visit. The amount of patients who decreased the dose are reported.

  6. Change in Quality of Life

    Time frame: Baseline and 12 Months

    Subjects were provided with the Euroqol-5 dimensions (EQ-5D) questionnaire at baseline and 12 Months follow-up visit. In that questionnaire, subjects were asked to indicate a score for their health on a scale where 100 would mean 'the best state he/she can imagine' and 0 would be the 'worst state he/she can imagine).

  7. Rate of Serious Adverse Events and/or Procedure/Device-related Adverse Events

    Time frame: from enrollment to 12 months follow up

    Adverse device effects were defined as adverse events related to the study procedures or the device. Serious events were those that resulted in-patient or prolonged hospitalization or were life-threatening.

  8. Paresthesia Mapping at 3 Months Compared to the Empower Study

    Time frame: 3 Months

    Paresthesia mapping is expressed in percent of paresthesia areas as indicated by the patient on a gender specific body diagram. 87 subjects with Burst stimulation at 3 Months (Prodigy-I) were compared to 134 subjects with tonic stimulation at 3 Months (Empower).

Sponsors and collaborators

Lead sponsor

Abbott Medical Devices

Industry

Registry information

Official study title

A Post-market Study Evaluating the Prodigy Neuromodulation System for the Management of Failed Back Surgery Syndrome or Chronic Intractable Pain of the Trunk and/or Limbs.

Acronym: Prodigy-I

Important dates

Study start
2014
Primary completion
2016
Study completion
2016
First posted
May 21, 2014
Registry last updated
Jul 8, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.